Lipoprotein apheresis in Austria – Reduction of cardiovascular events by regular lipoprotein apheresis treatment

2019 ◽  
Vol 40 ◽  
pp. 8-11
Author(s):  
Theresa Berent ◽  
Kurt Derfler ◽  
Robert Berent ◽  
Helmut Sinzinger
Keyword(s):  
Cardiovascular Events ◽  
Lipoprotein Apheresis

scholarly journals Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?

2020 ◽  
Vol 7 (3) ◽  
pp. 25
Author(s):  
Ulrich Julius ◽  
Solveig Kuss ◽  
Sergey Tselmin ◽  
Ulrike Schatz ◽  
Stefan R. Bornstein
Keyword(s):  
Cardiovascular Events ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density Lipoprotein Cholesterol ◽  
Lipoprotein Apheresis ◽  
Younger Age ◽  
Target Values ◽  
Risk Patients ◽  
Extracorporeal Therapy ◽  
Apheresis Therapy

Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of the LA therapy. We compared personal and lab data in two groups: CVEx/0 (n 60) with no new events during LA therapy, CVEx/1+ (n 48) with at least one new event. Patients of Group CVEx/1+ were about 5 years older when they had started the extracorporeal therapy, and they experienced more CVEs prior to that timepoint. There was a positive correlation between the number of CVEs before and during LA therapy. No differences were seen with respect to lipid concentrations, even after a correction of LDL-C concentrations for the LDL-C transported with Lp(a) particles. LA sessions effectively reduced both LDL-C and Lp(a). Lp(a) levels measured before LA sessions were lower than those measured initially. It appeared difficult to reach the target values for LDL-C published in the ESC/EAS Guideline in 2019, although all patients were maximally treated including drugs when tolerated. In conclusion, it will be important to initiate an LA therapy earlier, at least after a second CVE and at a younger age.

Factors inducing cardiovascular events in patients treated by lipoprotein apheresis

2013 ◽  
Vol 14 (1) ◽  
pp. 45-50 ◽  
Author(s):  
K. Taseva ◽  
S. Fischer ◽  
J. Passauer ◽  
N. Weiss ◽  
S.R. Bornstein ◽  
...  
Keyword(s):  
Cardiovascular Events ◽  
Lipoprotein Apheresis

Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study

2018 ◽  
Vol 57 (5) ◽  
pp. 661-664 ◽  
Author(s):  
Federico Bigazzi ◽  
Francesco Sbrana ◽  
Daniele Berretti ◽  
Zenti Maria Grazia ◽  
Sabina Zambon ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cardiovascular Events ◽  
Lipoprotein Apheresis

Cardiovascular events in patients treated by lipoprotein apheresis (LA) – Analysis of possible reasons

2016 ◽  
Vol 252 ◽  
pp. e215-e216
Author(s):  
S. Tselmin ◽  
S. Fischer ◽  
F. Pistrosch ◽  
G. Müller ◽  
U. Julius
Keyword(s):  
Cardiovascular Events ◽  
Lipoprotein Apheresis

scholarly journals Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)

Antioxidants ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 132
Author(s):  
Tina Z. Khan ◽  
Adam Hartley ◽  
Dorian Haskard ◽  
Mikhail Caga-Anan ◽  
Dudley J. Pennell ◽  
...  
Keyword(s):  
Cardiovascular Events ◽  
Controlled Trial ◽  
Refractory Angina ◽  
Oxidised Ldl ◽  
Lipoprotein A ◽  
Lipoprotein Apheresis ◽  
Atherosclerotic Burden ◽  
Significant Change ◽  
Randomised Controlled ◽  
Antibody Levels

Aims: An abundance of epidemiological evidence demonstrates that elevated lipoprotein(a) (Lp(a)) represents a significant contributing risk factor towards the development of cardiovascular disease. In particular, raised Lp(a) may play a mechanistic role in patients with refractory angina. Studies have also shown a correlation between oxidised LDL (oxLDL) levels and atherosclerotic burden as well as rates of cardiovascular events. Antibodies against oxLDL (anti-oxLDL) are involved in the removal of oxLDL. Lipoprotein apheresis (LA), which removes lipoproteins using extra-corporeal processes, is an established means of reducing Lp(a), and thereby reduces cardiovascular events. The aim of this study was to investigate the effect of LA on oxLDL and anti-oxLDL levels amongst those with refractory angina in the context of raised Lp(a). Methods: We performed a sub-study within a randomised controlled crossover trial involving 20 patients with refractory angina and raised Lp(a) > 500 mg/L, comparing the effect of three months of blinded weekly LA or sham, followed by crossover to the opposite study arm. We utilized enzyme-linked immunosorbent assays (ELISA) to quantify oxLDL and IgG/ IgM anti-oxLDL antibody levels at baseline and following three months of active LA or sham sessions. Results: Following three months of LA, there was a 30% reduction in oxLDL from 0.37 ± 0.06 to 0.26 ± 0.04 with a mean drop of −0.11 units (U) (95% CI −0.13, −0.09) compared to no significant change with sham therapy (p < 0.0001 between treatment arms). LA also led to a 22% reduction in levels of IgG and IgM anti-oxLDL, again with no significant change demonstrated during sham (p = 0.0036 and p = 0.012, respectively, between treatment arms). Conclusion: Amongst patients with refractory angina in the context of elevated Lp(a), LA significantly lowers levels of oxLDL and anti-oxLDL antibodies, representing potential mechanisms by which LA yields symptomatic and prognostic benefits in this patient cohort.

Sign in / Sign up

Export Citation Format

Share Document